Form 4: Lyra Therapeutics Insider Trades Common Stock

Jason Cavalier, Principal Financial Officer at Lyra Therapeutics, Inc., reported a transaction involving 667 shares of common stock on April 1, 2026.

Summary

• Jason Cavalier, the Principal Financial Officer of Lyra Therapeutics, Inc., reported a transaction on April 1, 2026.
• The transaction involved the acquisition of 667 shares of common stock.
• These shares were acquired at a price of $0, indicating they were likely granted or awarded.
• Following this transaction, Mr. Cavalier beneficially owns 517,880 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports a routine insider transaction without providing new financial or strategic information.

Positives

• Insider acquisition of shares can signal confidence in the company's future prospects.
• The acquisition of 667 shares by a key executive indicates continued alignment with shareholder interests.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive and director holdings. Such filings are crucial for investors monitoring insider sentiment, though they do not typically contain strategic or financial performance data.

Stakeholder Impact

• Shareholders: Increased transparency regarding insider holdings, potentially signaling confidence from management.

Key Dates

Keywords

Lyra Therapeutics, Form 4, Insider Trading, Common Stock, Beneficial Ownership, SEC Filing, Jason Cavalier